Life Sciences DNA Podcast

Driving Insights from Real World Oncology Data with AI

Aaron Cohen, Head of Research Oncology, Clinical Data for Flatiron Health, sits down with Amar Drawid to discuss Flatiron’s use of large language models to extract and analyze unstructured data from electronic health records. Cohen discusses how AI‑extracted data can replicate human‑curated outcomes across multiple cancer types, paving the way for faster, richer insights to guide both clinical decision‑making and drug development.

Improving Drug Development with Real-World Data

Manfred Stapff, founder and principal of Candid Advisory, sits down with Amar Drawid to discuss the potential of real-world data to accelerate drug development and improve regulatory strategies. He discusses why real-world data can provide insights may miss, shed light on treatment effects once approved, and how it may one day reshape the drug approval process.

Navigating the AI Landscape in Clinical Development

Stephen Pyke, chief clinical data and digital officer at Parexel, sits down with Srivatsan Nagaraja to discuss the adoption of AI technologies in clinical development. He highlights the importance of workflow integration, the challenges of change management, and how to prepare organizations for an AI-driven future.

Transforming Cancer Diagnostics and Care with AI

Mohan Uttarwar, CEO 1Cell.Ai, sits down with Amar Drawid to discuss how his company is transforming cancer diagnostics and care by combining cutting-edge molecular science with advanced AI. He talks about how the company’s single-cell multi-omics platform provides real-time, precision insights, enhances patient selection in clinical trials, and delivers actionable information for oncologists.

Moving Beyond the Hype of AI in Biopharma

Amar Drawid, vice president and global head of data analytics, insights, and AI for BioNTech, sits down with Nagaraja Srivatsan to discuss the evolution, adoption, and challenges of AI in the biopharma sector. He discusses the real-world implementation challenges of generative AI, the iterative process of developing business solutions, and the necessity of effective change management for organizational adoption.

Why AI’s Most Promising Near-Term Value Is in Clinical Operations

Dimitris Agrafiotis, director of digital analytics and AI at Arsenal Capital Partners sits down with Nagaraja Srivatsan to discuss the current state of AI in clinical trials, the potential for AI to streamline operations, and the importance of user experience and change management in driving adoption of the technology.

Teaching the Biopharma Workforce to Coexist with AI

Sunil Talathi, senior director and head of data insights, data sciences, and analytics for BeOne Medicines; sits down with Nagaraja Srivatsan to discuss his experience implementing AI in a biopharmaceutical company. He discusses cost considerations, prompt engineering, and the need for collaboration between humans and AI systems.

Making Clinical Trials More Predictable with AI

Craig Lipset, advisor and founder of Clinical Innovation Partners, sits down with Nagaraja Srivatsan to discuss how AI can bring greater predictability to clinical trials, how organizations can adopt the technology effectively, and the importance of having a culture of experimentation.